Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001061980 | SCV001226749 | likely benign | Saldino-Mainzer syndrome | 2025-01-12 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003283944 | SCV004004878 | uncertain significance | Inborn genetic diseases | 2023-04-14 | criteria provided, single submitter | clinical testing | The c.4309G>A (p.E1437K) alteration is located in exon 31 (coding exon 29) of the IFT140 gene. This alteration results from a G to A substitution at nucleotide position 4309, causing the glutamic acid (E) at amino acid position 1437 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Dept Of Ophthalmology, |
RCV003890211 | SCV004704938 | likely benign | Retinal dystrophy | 2023-10-01 | criteria provided, single submitter | research | |
Fulgent Genetics, |
RCV005021403 | SCV005642688 | uncertain significance | Saldino-Mainzer syndrome; Retinitis pigmentosa 80 | 2024-06-20 | criteria provided, single submitter | clinical testing |